RenovoRx, Inc. Common Stock (RNXT) Stock Price

RNXTStock
$1.14−2.56%52W
Market Cap$51.45M
P/E—
PEG Ratio—
Div yield—
Beta1.10

RNXT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)0.77%
Price vs S&P 500 (4W)-30.41%
VGM Score60.84

RNXT Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.07-$0.05+33.33%(+$0.02)
Q1 2026-$0.08-$0.08-4.34%(-$0.00)
Q4 2025-$0.08-$0.08+0.00%(+$0.00)
Q3 2025-$0.08-$0.08+0.00%(+$0.00)
Q2 2025-$0.08-$0.08+0.00%(+$0.00)

RNXT Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.10
4.10
4.10
4.10

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
RNXTRenovoRx, Inc. Common Stock
DAB26.0x—84.4%—$1.14
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About RenovoRx, Inc. Common Stock

RenovoRx is a clinical-stage biopharmaceutical company developing targeted combination cancer therapies. Its proprietary Trans-Arterial Micro-Perfusion platform delivers therapeutics directly to tumors to potentially enhance efficacy while reducing toxicities compared to systemic intravenous therapy.